



www.genfit.com

VISIT OF MR. ARNAUD MONTEBOURG, FRENCH INDUSTRY MINISTER

Lille (France), Boston (Massachusetts, United States), November 16th, 2012 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that the French Industry Minister, Mr. Arnaud MONTEBOURG, visited its headquarters yesterday, as part of a ministerial visit particularly focused on the Nutrition-Health-Longevity competitiveness cluster of which the Company is a key player.

The presentation of the Company's activities during this visit illustrated the benefits of the policy of decompartmentalization between academic and industrial research that GENFIT exemplifies in the interest of therapeutic innovation.

Mr. MONTEBOURG emphasized the exemplary development model of GENFIT, that has collaborated since its inception with major international pharmaceutical industry players and also with multiple academic research institutions, at the local, national, and European level.

Questioned by the Minister about the initiatives likely to further encourage this policy of crossover innovation and to reap the benefits for the competitiveness of the French biopharmaceutical industry, Jean-Francois MOUNEY, Chairman and Chief Executive Officer of GENFIT and Vice-President of the Nutrition-Health-Longevity competitiveness cluster, particularly praised the Research Tax Credit (CIR) and the calls for R&D proposals supported by the Unique Interministerial Fund (FUI), as well as the associated support for innovation shown by the French public organization for innovation OSEO. He stated that these measures *«enable biotechnology companies, major sources of innovation for the pharmaceutical industry, to devote significant financial means to the initial stages of applied therapeutic research in collaboration with academic researchers»*. Mr. MOUNEY also indicated that *«French public and private funding to continue these efforts with the aim of medium-term economic valorization and that should allow biotechnology companies to play their bridging role with the pharmaceutical industry, remain insufficient in the international context, pending the role of the Public Investment Bank in this field»*.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr